更年期潮熱治療市場-全球行業規模、份額、趨勢、機會和預測，2018-2028 年，按類型、按治療類型、按分銷渠道、按地區、競爭

全球更年期潮熱治療市場預計在預測期內將出現顯著增長。

這可能是由於採用替代管理方法的產品的技術進步。 此外，預計醫療保健公司對非激素藥物臨床試驗的激增也將推動預測期內的市場增長。 此外，全球老年婦女的數量正在飆升，預計更年期潮熱症狀會增加。 出於這個原因，我們預計未來幾年會出現顯著增長。 此外，由於公共機構和私營公司的努力，女性健康意識的提高也有望刺激市場增長。 根據 2020 年 12 月發表的《女性經常潮熱，40 至 65 歲患有代謝綜合徵》的研究，大約 55.83% 的 40 歲以上女性容易發燒，這似乎與代謝綜合徵有關。是。 對潮熱研究和開發的日益關注也推動了市場增長。

更年期潮熱增加

由於酒精、吸煙和垃圾食品消費，更年期潮熱的發病率上升進一步推動了預測期內的市場增長。 此外，隨著新療法的批准，人們對新的更年期潮熱療法的認識不斷提高，預計也將推動這些年來的市場增長。 美國每年約有 75-80% 的更年期婦女出現潮熱。 這是一種快速變暖的感覺，主要影響胸部、頸部和麵部，也是預計推動市場增長的一些關鍵因素。 在女性人群中經常發現雌激素水平波動和肌肉骨骼健康狀況不佳。 此外，新興市場參與者正在投資開發新療法，這將在預測期內進一步推動市場增長。 73% 的女性人口因疲勞、認知能力下降、睡眠障礙和生活質量下降以及醫療資源使用增加而出現絕經後潮熱，預計在預測期內將繼續進行更年期潮熱治療。可能需要。 85% 的更年期婦女因血管舒縮不穩定而出現繼發性潮熱（閃光）、盜汗和睡眠障礙。

醫療保健領域不斷創新

治療更年期潮熱的醫療技術不斷創新，我們正在與各大公司合作開發新設備，以幫助患有更年期潮熱綜合症的女性。 公司正在開發新設備以減少更年期潮熱。 例如，Menopod Instant Cooler 可以塗抹在頸背上以減輕潮熱的嚴重程度，並且是一款便攜式 USB 快速充電設備。 這些用作女性個人恆溫器的智能手錶型設備預計將在預測期內進一步推動市場增長。 此外，公司正在投資開發具有可調節冷卻和加熱溫度的可定制床墊市場，預計這將在預測期內進一步推動市場增長。 2010 年，美國估計有 5000 萬絕經後婦女。 根據美諾瑪莎國際更年期名錄，其中約有 4500 萬人超過 52 歲，這是西方國家自然絕經的平均年齡。 到 2020 年，估計美國 51 歲以上的女性將超過 5000 萬。

近期發展

• 美國食品和藥物管理局於 2022 年 6 月接受了 Astellas Pharma Inc. 的 fesolinetant 新藥申請 (NDA)。 （食品藥品監督管理局）。 fesolinetant 是一種實驗性口服非激素藥物，正在等待批准用於治療與更年期相關的輕度至重度血管舒縮症狀 (VMS)。
• 2021 年 2 月，Astellas Pharma Inc. 宣布啟動 fezolinetant 的 SKYLIGHT 1 和 SKYLIGHT 3 期關鍵臨床試驗，這是一種口服非激素化合物，正在研究用於治療中度至重度血管舒縮症狀 (VMS)。2 給予好的結果。
• 2020 年 1 月，拜耳通過收購 Vividion Therapeutics 加強了其藥物發現平台。 Vividion Therapeutics 為不同的適應症生產各種小分子療法，最初的重點是與腫瘤學和免疫學相關的靶點。

可用的自定義

根據市場數據，TechSci Research 根據公司的具體需求提供定制服務。 該報告可以定制為：

公司信息

• 對其他市場參與者（最多 5 家公司）進行深入分析和概況分析

內容

第 1 章概述

• 市場定義
• 市場範圍
  • 目標市場
  • 研究目標年份
  • 主要市場細分

第二章研究方法論

• 調查目的
• 基線調查方法
• 主要行業合作夥伴
• 主要協會和次要信息
• 調查方法
• 數據三角測量和驗證
• 假設和限制

第 3 章執行摘要

• 市場概覽
• 主要市場細分概述
• 主要市場參與者概覽
• 主要地區/國家概覽
• 市場驅動因素、挑戰和趨勢

第 4 章 VOC（客戶之聲）

第 5 章更年期潮熱藥物的全球市場展望

• 市場規模和預測
  • 按金額
• 市場份額和預測
  • 按類型（口服液/片劑）
  • 按治療類型（激素治療、非激素治療、替代治療）
  • 按分銷渠道（醫院藥店、零售藥店、在線藥店）
  • 按地區
  • 按公司分類（2022 年）
• 產品地圖

第六章北美更年期潮熱藥物市場展望

• 市場規模和預測
  • 按金額
• 市場份額和預測
  • 按類型（口服液/片劑）
  • 按治療類型（激素治療、非激素治療、替代治療）
  • 按分銷渠道（醫院藥店、零售藥店、在線藥店）
  • 按國家
• 北美：國家/地區分析
  • 美國
  • 加拿大
  • 墨西哥

第7章歐洲更年期潮熱藥物市場展望

• 市場規模和預測
  • 按金額
• 市場份額和預測
  • 按類型（口服液/片劑）
  • 按治療類型（激素治療、非激素治療、替代治療）
  • 按分銷渠道（醫院藥店、零售藥店、在線藥店）
  • 按國家
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 意大利
  • 西班牙

第 8 章亞太更年期潮熱治療市場展望

• 市場規模和預測
  • 按金額
• 市場份額和預測
  • 按類型（口服液/片劑）
  • 按治療類型（激素治療、非激素治療、替代治療）
  • 按分銷渠道（醫院藥店、零售藥店、在線藥店）
  • 按國家
• 亞太地區：國家/地區分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳大利亞

第 9 章南美洲更年期潮熱治療市場展望

• 市場規模和預測
  • 按金額
• 市場份額和預測
  • 按類型（口服液/片劑）
  • 按治療類型（激素治療、非激素治療、替代治療）
  • 按分銷渠道（醫院藥店、零售藥店、在線藥店）
  • 按國家
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章中東和非洲更年期潮熱藥物市場展望

• 市場規模和預測
  • 按金額
• 市場份額和預測
  • 按類型（口服液/片劑）
  • 按治療類型（激素治療、非激素治療、替代治療）
  • 按分銷渠道（醫院藥店、零售藥店、在線藥店）
  • 按國家
• MEA：國家分析
  • 南非更年期潮熱療法
  • 沙特更年期潮熱療法
  • 阿聯酋更年期潮熱治療

第 11 章市場動態

• 司機
• 任務

第12章市場趨勢與發展

• 近期發展狀況
• 併購
• 產品發布

第 13 章全球更年期潮熱藥物市場：SWOT 分析

第 14 章波特的五力分析

• 行業競爭
• 新進入的可能性
• 供應商的力量
• 客戶力量
• 替代品的威脅

第15章競爭格局

• 業務概覽
• 提供的產品
• 近期發展狀況
• 財務（據報導）
• 主要人物
• SWOT 分析
  • Abbvie, Inc.
  • Allergan PLC.
  • Bayer Ag.
  • Cipla, Inc.
  • Eli Lilly and Company.
  • Emcure Pharmaceuticals Ltd.
  • GSK PLC.
  • Glenmark Pharmaceuticals Ltd.
  • Hisamitsu Pharmaceutical Co. Inc.
  • Merck & Co. Inc.
  • Novartis Ag.
  • Novo Nordisk AS.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • TherapeuticsMD, Inc.

第16章 戰略建議

Global Menopausal Hot Flashes Treatment market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the increasing technological advancements in products with alternative administration modes. Similarly, a rapid increase in clinical trials by healthcare companies in non-hormonal products is further expected to boost market growth during the forecast period. Moreover, a rapid increase in the number of elderly women across the globe is expected to increase menopausal hot flashes symptoms. This, in turn, is expected to create significant growth over the years. Moreover, increasing awareness about women's health on the back of public as well as private initiatives may fuel the growth of the market over the years. According to the study "Frequent hot flashes in women, 40 to 65 years of age with metabolic syndrome," published in December 2020, women over the age of 40 are more likely to have a fever, about 55.83%, and appear to be associated with metabolic syndrome. Growing focus on research and development of hot flashes is also driving the growth of the market.

Growing Incidences of Menopausal Hot Flashes

The growing incidence of menopausal hot flashes due to the consumption of alcohol, smoking, and junk foods is further boosting the market growth during the forecast period. Also, growing approval for new treatments, along with growing awareness about new menopausal hot flashes treatments, will drive the market growth over the years. Hot flashes occur in approximately 75 to 80% of menopausal women in the United States every year. It's a quick sensation of warmth that basically affects the chest, neck, and face and is also some of the main factors which are expected to drive market growth. High prevalence of fluctuating oestrogen levels and deteriorating musculoskeletal health among the women population. Moreover, new market players are investing in the development of new treatments, which will further boost the market growth during the forecast period. 73% of women in the women population have post-menopausal hot flashes due to fatigue, reduced cognitive function, sleep difficulties, and lowering their quality of life along with growing usage of medical resources, which will further demand menopausal hot flashes treatment during the forecast period. As many as 85% of perimenopausal women experience hot flashes (flushes), night sweats, and/or sleep disturbances secondary to vasomotor instability.

Growing Innovation in Medicine

Growing innovation in medicine for the treatment of menopausal hot flashes, along with major companies, is focusing on the development of new devices which will help women with menopausal hot flashes syndrome. Companies are developing a new device that reduces menopausal hot flashes. For instance, Menopod instant cooling devices, when applied to the neck, help alleviate the severity of hot flashes, and it is a portable, quick USB charging device. These smartwatch-like devices used as personal thermostats for women are further expected to boost the market growth during the forecast period. Moreover, companies are investing in the development of customizable mattresses that offer cooling and heating temperature controls which will further boost the market growth during the forecast period. There were an estimated 50 million postmenopausal women in the United States in 2010. According to Meno Martha International Menopause Directory, about 45 million of them were aged older than 52 years, the average age of natural menopause in the Western world. In 2020, the number of women aged more than 51 years was estimated to cross 50 million in the United States.

Market Segmentation

Global Menopausal Hot Flashes Treatment market can be segmented on the basis of type, treatment type, distribution channel, and by region. Based on type, the market can be further bifurcated into oral liquid and pill. Based on treatment type, the market can be further divided into hormonal treatment, non-hormonal treatment, and alternative treatment. Based on distribution channels, the market is further split into hospital pharmacies, retail pharmacies, and online pharmacies. On the basis of region, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. On the basis of countries, the United States dominated the global Menopausal Hot Flashes Treatment market on account of the increasing number of women reaching menopausal age.

Recent Developments

• The U.S. Food and Drug Administration received a new drug application (NDA) for fezolinetant from Astellas Pharma Inc. in June 2022. (FDA). For the treatment of mild to severe vasomotor symptoms (VMS) related to menopause, the experimental oral, nonhormonal chemical fezolinetant is awaiting approval.
• In February 2021, Astellas Pharma Inc. announced the positive results from the Phase 3 pivotal SKYLIGHT 1 and SKYLIGHT 2 clinical trials of fezolinetant, which is an oral, non-hormonal compound being tested for the treatment of moderate to severe vasomotor symptoms (VMS).
• In January 2020, Bayer AG strengthened its drug discovery platform through the acquisition of Vividion Therapeutics. Vividion Therapeutics produces a variety of small molecule therapies across indications, and their initial focus was on targets relevant to oncology and immunology.

Market Players

Abbvie, Inc., Allergan PLC., Bayer AG., Cipla, Inc., Eli Lilly and Company, Emcure Pharmaceuticals Ltd., GSK PLC., Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Merck & Co. Inc., Novartis Ag., Novo Nordisk AS., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and TherapeuticsMD, Inc. are some of the leading players operating in the Global Menopausal Hot Flashes Treatment Market.

Report Scope

In this report, the global Menopausal Hot Flashes Treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Menopausal Hot Flashes Treatment Market, By Type:

• Oral Liquid
• Pill

Menopausal Hot Flashes Treatment Market, By Treatment Type:

• Hormonal Treatment
• Non-Hormonal Treatment
• Alternative Treatment

Menopausal Hot Flashes Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Menopausal Hot Flashes Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Menopausal Hot Flashes Treatment Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Menopausal Hot Flashes Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Oral Liquid v/s Pill)
  • 5.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
    • 5.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
    • 5.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
    • 5.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Product Map

6. North America Menopausal Hot Flashes Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Oral Liquid v/s Pill)
  • 6.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
    • 6.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
    • 6.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
    • 6.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Menopausal Hot Flashes Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Menopausal Hot Flashes Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Menopausal Hot Flashes Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By Distribution Channel

7. Europe Menopausal Hot Flashes Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Oral Liquid v/s Pill)
  • 7.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
    • 7.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
    • 7.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
    • 7.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Menopausal Hot Flashes Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Menopausal Hot Flashes Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Oral Liquid v/s Pill)
  • 8.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
    • 8.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
    • 8.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
    • 8.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Menopausal Hot Flashes Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By Distribution Channel

9. South America Menopausal Hot Flashes Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Oral Liquid v/s Pill)
  • 9.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
    • 9.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
    • 9.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
    • 9.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Menopausal Hot Flashes Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Menopausal Hot Flashes Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Menopausal Hot Flashes Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Menopausal Hot Flashes Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Oral Liquid v/s Pill)
  • 10.2.2. By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment)
    • 10.2.2.1 Hormonal Treatment (Oestrogen, Oestrogen-Progesterone Combination, Progesterone)
    • 10.2.2.2 Non-Hormonal Treatment (Clonidine, Gabapentin, Pregabalin, Brisdelle, Antidepressants)
    • 10.2.2.3 Alternative Treatment (Vitamin E, Herbal Medicines, Black Cohosh)
  • 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Menopausal Hot Flashes Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Menopausal Hot Flashes Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Menopausal Hot Flashes Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Menopausal Hot Flashes Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Product Offerings
• 15.3. Recent Developments
• 15.4. Financials (As Reported)
• 15.5. Key Personnel
• 15.6. SWOT Analysis
  • 15.6.1 Abbvie, Inc.
  • 15.6.2 Allergan PLC.
  • 15.6.3 Bayer Ag.
  • 15.6.4 Cipla, Inc.
  • 15.6.5 Eli Lilly and Company.
  • 15.6.6 Emcure Pharmaceuticals Ltd.
  • 15.6.7 GSK PLC.
  • 15.6.8 Glenmark Pharmaceuticals Ltd.
  • 15.6.9 Hisamitsu Pharmaceutical Co. Inc.
  • 15.6.10 Merck & Co. Inc.
  • 15.6.11 Novartis Ag.
  • 15.6.12 Novo Nordisk AS.
  • 15.6.13 Pfizer, Inc.
  • 15.6.14 Teva Pharmaceutical Industries Ltd.
  • 15.6.15 TherapeuticsMD, Inc.

16. Strategic Recommendations